Yaprak Gokhan, Tataroglu Deniz, Dogan Bedriye, Pekyurek Melike
Department of Radiation Oncology, University of Health Sciences, Kartal Dr. Lutfi Kırdar Training and Research Hospital, Istanbul, Turkey.
Department of Medical Oncology, University of Health Sciences, Kartal Dr. Lutfi Kırdar Training and Research Hospital, Istanbul, Turkey.
North Clin Istanb. 2019 Dec 5;7(2):146-152. doi: 10.14744/nci.2019.73549. eCollection 2020.
We aimed to investigate survival outcomes and survival-related prognostic factors in gastric cancer patients who were followed-up or received adjuvant therapy in our center.
Patients with gastric cancer treated between 2005 and 2016 were evaluated retrospectively. We included 345 non-metastatic (stage I-III) gastric cancer patients in the study. The clinical, demographic, histologic data of the patients and treatment characteristics were obtained from the patient's files.
While 50 patients were stage I, 94 patients were stage II, 201 patients were stage III. While 221 patients (64%) presenting with serosal or adjacent visceral organ invasion or with involved lymph nodes were treated with adjuvant chemoradiotherapy, 124 patients presenting with early-stage disease were followed after surgery. Median follow up time was 34 months (4-156 months). While the median overall survival (OS) was 51 months, median disease-free survival (DFS) was 35 months. Overall survival and disease-free survival rates for 1, 3 and 5 years were 85%, 55%, 45% and 72%, 49%, 38%, respectively. According to univariate analysis, tumor size, T stage (p<0.001), N stage (p<0.001), TNM stage (p<0.001), grade (p<0.001) and presence of lymphovascular invasion (p=0.005) were determined as prognostic factors that affect overall survival significantly. According to the multivariate analysis, only T and N stage (p<0.001) were determined as independent prognostic factors for overall survival.
Many different prognostic factors have been defined for gastric cancer. In concordance with the literature, we found T and N stages as prognostic factors in univariate and multivariate analysis.
我们旨在研究在本中心接受随访或辅助治疗的胃癌患者的生存结局及与生存相关的预后因素。
对2005年至2016年间接受治疗的胃癌患者进行回顾性评估。本研究纳入了345例非转移性（I - III期）胃癌患者。患者的临床、人口统计学、组织学数据及治疗特征均从患者病历中获取。
其中50例为I期，94例为II期，201例为III期。221例（64%）出现浆膜或临近内脏器官侵犯或有受累淋巴结的患者接受了辅助放化疗，124例早期疾病患者术后进行随访。中位随访时间为34个月（4 - 156个月）。中位总生存期（OS）为51个月，中位无病生存期（DFS）为35个月。1年、3年和5年的总生存率和无病生存率分别为85%、55%、45%和72%、49%、38%。单因素分析显示，肿瘤大小、T分期（p<0.001）、N分期（p<0.001）、TNM分期（p<0.001）、分级（p<0.001）及淋巴管侵犯情况（p = 0.005）被确定为显著影响总生存的预后因素。多因素分析显示，只有T分期和N分期（p<0.001）被确定为总生存的独立预后因素。
胃癌已被定义了许多不同的预后因素。与文献一致，我们在单因素和多因素分析中均发现T分期和N分期为预后因素。
